Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription


2 AJR Am J Roentgenol
1 BJU Int
1 BMC Cancer
2 BMC Urol
4 Cancer
3 Eur J Radiol
1 Eur Radiol
2 Int J Radiat Oncol Biol Phys
2 J Magn Reson Imaging
4 J Nucl Med
1 J Urol
2 Nat Rev Urol
1 PLoS Med
1 PLoS One
5 Prostate
1 Radiol Imaging Cancer
1 Ther Adv Urol
1 Urol Int
2 Urology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

    Editorial Comment: Directions for Further Literature on the Role of PET in Biochemical Recurrence of Prostate Cancer.
    AJR Am J Roentgenol. 2021 Aug 25. doi: 10.2214/AJR.21.26706.

  2. BHAYANA R, O'Shea A, Anderson MA, Bradley WR, et al
    PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
    AJR Am J Roentgenol. 2021;217:141-151.
    PubMed         Abstract available

    BJU Int

  3. URIBE-LEWIS S, Uribe J, Bourke V, Deering C, et al
    Long-term survival after LDR Brachytherapy for Prostate Cancer: the Royal Surrey experience.
    BJU Int. 2021 Aug 27. doi: 10.1111/bju.15585.
    PubMed         Abstract available

    BMC Cancer

  4. ANDKHOIE M, Szafron M
    Geographic disparities in Saskatchewan prostate cancer incidence and its association with physician density: analysis using Bayesian models.
    BMC Cancer. 2021;21:948.
    PubMed         Abstract available

    BMC Urol

  5. LEE HH, Joung JY, Kim SH
    The effect of subsequent immunosuppressant use in organ-transplanted patients on prostate cancer incidence: a retrospective analysis using the Korean National Health Insurance Database.
    BMC Urol. 2021;21:112.
    PubMed         Abstract available

  6. JIANG L, Bai Z, Zhu S, Zhao T, et al
    A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report.
    BMC Urol. 2021;21:114.
    PubMed         Abstract available


  7. PATEL HD, Koehne EL, Shea SM, Bhanji Y, et al
    Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: A prospective evaluation of the PLUM cohort.
    Cancer. 2021 Aug 24. doi: 10.1002/cncr.33875.
    PubMed         Abstract available

    Prostate cancer and the added burden of COVID-19 in sub-Saharan Africa: Rethinking regional priorities for responsive and data-driven cancer control programs.
    Cancer. 2021 Aug 23. doi: 10.1002/cncr.33887.

  9. NGUYEN DD, Trinh QD, Cole AP, Kilbridge KL, et al
    Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States.
    Cancer. 2021;127:249-256.
    PubMed         Abstract available

  10. LAUTZ TB, Chi YY, Li M, Wolden SL, et al
    Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group.
    Cancer. 2021;127:275-283.
    PubMed         Abstract available

    Eur J Radiol

  11. FERDINANDUS J, Fendler WP, Morigi JJ, Fanti S, et al
    Theranostics in oncology: What radiologists want to know.
    Eur J Radiol. 2021;142:109875.
    PubMed         Abstract available

  12. GMEINER J, Garstka N, Helbich TH, Shariat SF, et al
    Vesical Imaging Reporting and Data System (VI-RADS): Are the individual MRI sequences equivalent in diagnostic performance of high grade NMIBC and MIBC?
    Eur J Radiol. 2021;142:109829.
    PubMed         Abstract available

  13. YOUN SY, Choi MH, Kim DH, Lee YJ, et al
    Detection and PI-RADS classification of focal lesions in prostate MRI: Performance comparison between a deep learning-based algorithm (DLA) and radiologists with various levels of experience.
    Eur J Radiol. 2021;142:109894.
    PubMed         Abstract available

    Eur Radiol

  14. REISCHAUER C, Cancelli T, Malekzadeh S, Froehlich JM, et al
    How to improve image quality of DWI of the prostate-enema or catheter preparation?
    Eur Radiol. 2021;31:6708-6716.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  15. NUIJENS AC, Oei AL, van Oorschot B, Visser J, et al
    Gamma-H2AX Foci Decay Ratio as a Stronger Predictive Factor of Late Radiation Toxicity than Dose-Volume Parameters in a Prospective Cohort of Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021 Aug 19. pii: S0360-3016(21)02708.
    PubMed         Abstract available

  16. BRAND DH, Bruningk SC, Wilkins A, Fernandez K, et al
    Estimates of Alpha/Beta (alpha/beta) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
    Int J Radiat Oncol Biol Phys. 2021;110:596-608.
    PubMed         Abstract available

    J Magn Reson Imaging

  17. NAIR RT, Dawkins AA, Ganesh HS
    Editorial for "Diagnostic Performance of Prostate MRI Radiomics, Four Kallikrein Panel and Radiologist in the Detection of Prostate Cancer: A Retrospective External Validation Multi-center Study of Men With a Clinical Suspicion of Prostate Cancer".
    J Magn Reson Imaging. 2021 Aug 27. doi: 10.1002/jmri.27898.

    Editorial for "Biparametric Magnetic Resonance Imaging-Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index Lesion".
    J Magn Reson Imaging. 2021 Aug 23. doi: 10.1002/jmri.27897.

    J Nucl Med

  19. FAROLFI A, Hirmas N, Gafita A, Weber M, et al
    PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study.
    J Nucl Med. 2020 Sep 11. pii: jnumed.120.246603. doi: 10.2967/jnumed.120.246603.
    PubMed         Abstract available

  20. ZACHERL MJ, Gildehaus FJ, Mittlmeier L, Boning G, et al
    First Clinical Results for PSMA-Targeted alpha-Therapy Using (225)Ac-PSMA-I&T in Advanced-mCRPC Patients.
    J Nucl Med. 2021;62:669-674.
    PubMed         Abstract available

  21. LODGE MA, Lesniak W, Gorin MA, Pienta KJ, et al
    Measurement of PET Quantitative Bias In Vivo.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.251397. doi: 10.2967/jnumed.120.251397.
    PubMed         Abstract available

  22. MCINNES LE, Cullinane C, Roselt PD, Jackson S, et al
    Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with (67)Cu.
    J Nucl Med. 2021;62:829-832.
    PubMed         Abstract available

    J Urol

  23. KIM M, Wu S, Lin SX, Crotty RK, et al
    Transperineal Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy Combined with Standard Template Improves Prostate Cancer Detection.
    J Urol. 2021 Aug 25:101097JU0000000000002168. doi: 10.1097/JU.0000000000002168.
    PubMed         Abstract available

    Nat Rev Urol

  24. TURKBEY B, Wood BJ
    The need for standardization of reporting in prostate MRI.
    Nat Rev Urol. 2021;18:195-196.

  25. FENNER A
    Radiotheranostic targeting of fPSA.
    Nat Rev Urol. 2021;18:131.

    PLoS Med

  26. TIERNEY JF, Fisher DJ, Vale CL, Burdett S, et al
    A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials.
    PLoS Med. 2021;18:e1003629.
    PubMed         Abstract available

    PLoS One

  27. WEINER F, Schille JT, Hein JI, Wu XF, et al
    Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.
    PLoS One. 2021;16:e0256468.
    PubMed         Abstract available


  28. OKINAKA Y, Kageyama S, Nishizawa K, Yoshida T, et al
    Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan.
    Prostate. 2021 Aug 21. doi: 10.1002/pros.24212.
    PubMed         Abstract available

  29. SUN BL
    Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24213.
    PubMed         Abstract available

  30. LEON P, Cancel-Tassin G, Bourdon V, Buecher B, et al
    Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    Prostate. 2021;81:318-325.
    PubMed         Abstract available

  31. WENZEL M, Wurnschimmel C, Nocera L, Colla Ruvolo C, et al
    The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients.
    Prostate. 2021;81:339-346.
    PubMed         Abstract available

  32. WANG Z, Zhu S, Zhao J, Nie L, et al
    The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24215.
    PubMed         Abstract available

    Radiol Imaging Cancer

  33. REISAETER LAR, Halvorsen OJ, Beisland C, Honore A, et al
    Assessing Extraprostatic Extension with Multiparametric MRI of the Prostate: Mehralivand Extraprostatic Extension Grade or Extraprostatic Extension Likert Scale?
    Radiol Imaging Cancer. 2020;2:e190071.
    PubMed         Abstract available

    Ther Adv Urol

  34. CHUNG E
    Regenerative technology to restore and preserve erectile function in men following prostate cancer treatment: evidence for penile rehabilitation in the context of prostate cancer survivorship.
    Ther Adv Urol. 2021;13:17562872211026421.
    PubMed         Abstract available

    Urol Int

  35. PETERS R, Stephan C, Jung K, Lein M, et al
    Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort.
    Urol Int. 2021 Aug 25:1-6. doi: 10.1159/000517891.
    PubMed         Abstract available


  36. POSIELSKI N, Frankel J, Kuo HC, Ho O, et al
    Urology. 2021 Aug 21. pii: S0090-4295(21)00783.
    PubMed         Abstract available

  37. VINCE RA JR, Jamieson S, Mahal B, Iii WU, et al
    Examining the Racial Disparities in Prostate Cancer.
    Urology. 2021 Aug 18. pii: S0090-4295(21)00772.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.